Instructions for Authors

The abstract submitted to the Scientific Program Committee should have a maximum of 2500 characters. One image or table can be included in each abstract.

Submission and responsibilities of the corresponding author

To submit your abstract, please use to register and have access to the template and the submission process.

The first author listed for each abstract serves as the corresponding author for all correspondence regarding the abstract, unless otherwise specified. The corresponding author is responsible for the following:

  • Approval of all co-authors on the content of the abstract and agreement to be co-authors.

  • Informing all co-authors on any changes of the abstract.

  • Notifying all co-authors of the publication of accepted abstracts in a supplement of the Journal HemaSphere

Notification regarding acceptance of abstracts will be sent to the corresponding author via e-mail in August 2018. Abstracts of superior quality will be selected by the Scientific Program Committee for presentation at the ISHL11.

Once an abstract is submitted, a written request must be submitted no later than September 10, 2018, to if the corresponding author chooses to withdraw the abstract for any reason. Abstracts will not be withdrawn after this deadline.

Responsibilities of the Presenting Author

The presenting author must be one of the co-authors listed on the submitted abstract but does not need to be the corresponding author. It is the responsibility of the presenting author to obtain all of the conflict-of-interest disclosures from co-authors.

Abstract Submission

To submit your abstract, please use to register and have access to the template and the submission process.

ISHL10 Award Winners

Young Investigator Award

  • Naike Casagrande (T008)
  • Peter Hollander (T005)
  • Anna Lollies (T006)
  • Wouter Plattel (T014)
  • Carolin Bürkle (T025)

Karl Musshoff Prize: Best Basic Science Abstract

Arjan Diepstra

T009: Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?

Karl Musshoff Prize: Best Clinical Research Abstract

Pier Luigi Zinzani

T022: CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation

ISHL10 Haematologica Abstracts Book

ISHL10 Haematologica Abstracts Book

ISHL9 Haematologica Abstract Book

ISHL9 Haematologica Abstract Book